Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients.
Husam AlbarmawiMadhuram NagarajanEberechukwu OnukwughaAakash Bipin GandhiKaren N KeatingSreevalsa AppukkuttanJean YaredPublished in: Future oncology (London, England) (2020)
Aim: Characterize follicular lymphoma (FL) treatment patterns among elderly patients using a dataset with longer follow-up time. Materials & methods: Using the linked Surveillance, Epidemiology and End Results-Medicare data, we identified patients diagnosed with FL between 2000 and 2013 with claims data until 2014. We investigated the treatments received and assigned them to lines of treatment. Results: We identified 10,238 elderly patients. Over a 4.7-year median follow-up, 78% of the patients received at least first-line treatment. Fewer individuals received second-line (47%) and third-line (30%) treatments. RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone), RCVP (rituximab, cyclophosphamide, vincristine and prednisolone) and rituximab monotherapy were the most common treatment regimens. Conclusion: One in five elderly patients did not receive FL-directed therapy. The most common treatment regimens were limited to RCHOP, RCVP and rituximab monotherapy.
Keyphrases
- end stage renal disease
- diffuse large b cell lymphoma
- chronic kidney disease
- public health
- combination therapy
- healthcare
- peritoneal dialysis
- newly diagnosed
- stem cells
- machine learning
- prognostic factors
- open label
- mesenchymal stem cells
- big data
- study protocol
- artificial intelligence
- deep learning
- patient reported outcomes
- chronic lymphocytic leukemia